Search Results - "Bruin Weller, M."

Epidemiology of atopic dermatitis in adults: Results from an international survey by Barbarot, S., Auziere, S., Gadkari, A., Girolomoni, G., Puig, L., Simpson, E. L., Margolis, D. J., Bruin‐Weller, M., Eckert, L.

“…Background There are gaps in our knowledge of the prevalence of adult atopic dermatitis (AD). Objective To estimate the prevalence of AD in adults and by…”
Get full text

Conjunctivitis in dupilumab clinical trials by Akinlade, B., Guttman‐Yassky, E., Bruin‐Weller, M., Simpson, E.L., Blauvelt, A., Cork, M.J., Prens, E., Asbell, P., Akpek, E., Corren, J., Bachert, C., Hirano, I., Weyne, J., Korotzer, A., Chen, Z., Hultsch, T., Zhu, X., Davis, J.D., Mannent, L., Hamilton, J.D., Teper, A., Staudinger, H., Rizova, E., Pirozzi, G., Graham, N.M.H., Shumel, B., Ardeleanu, M., Wollenberg, A.

“…Summary Background Dupilumab blocks the shared receptor component for interleukin (IL)‐4 and IL‐13. It is approved in the U.S.A. for patients aged ≥ 12 years…”
Get full text

ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children by Wollenberg, A., Christen‐Zäch, S., Taieb, A., Paul, C., Thyssen, J.P., Bruin‐Weller, M., Vestergaard, C., Seneschal, J., Werfel, T., Cork, M.J., Kunz, B., Fölster‐Holst, R., Trzeciak, M., Darsow, U., Szalai, Z., Deleuran, M., Kobyletzki, L., Barbarot, S., Heratizadeh, A., Gieler, U., Hijnen, D.J., Weidinger, S., De Raeve, L., Svensson, Å., Simon, D., Stalder, J.F., Ring, J.

“…Atopic dermatitis (AD) is a highly pruritic, chronic inflammatory skin disease. The diagnosis is made using evaluated clinical criteria. Disease activity and…”
Get full text

Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo‐controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ) by Bruin‐Weller, M., Thaçi, D., Smith, C.H., Reich, K., Cork, M.J., Radin, A., Zhang, Q., Akinlade, B., Gadkari, A., Eckert, L., Hultsch, T., Chen, Z., Pirozzi, G., Graham, N.M.H., Shumel, B.

“…Summary Background Atopic dermatitis is a chronic inflammatory skin disease that may require systemic therapy. Ciclosporin A (CsA) is a widely used, potent…”
Get full text

ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients by Wollenberg, A., Oranje, A., Deleuran, M., Simon, D., Szalai, Z., Kunz, B., Svensson, A., Barbarot, S., von Kobyletzki, L., Taieb, A., de Bruin-Weller, M., Werfel, T., Trzeciak, M., Vestergard, C., Ring, J., Darsow, U.

“…Atopic dermatitis (AD) is a clinically defined, highly pruritic, chronic inflammatory skin disease of children and adults. The diagnosis is made using…”
Get full text

Conjunctivitis in adult patients with moderate‐to‐severe atopic dermatitis: results from five tralokinumab clinical trials by Wollenberg, A., Beck, L.A., Bruin Weller, M., Simpson, E.L., Imafuku, S., Boguniewicz, M., Zachariae, R., Olsen, C.K., Thyssen, J.P.

“…Summary Background Tralokinumab, a fully human IgG4 monoclonal antibody that specifically binds with high affinity to interleukin‐13, effectively reduces…”
Get full text

Systemic treatment in atopic dermatitis after 2018: from experienced‐based treatment to evidence‐based treatment? by Bruin‐Weller, M.

“…Linked Article: Vermeulen et al. Br J Dermatol 2020; 183:1073–1082…”
Get full text

Time to get rid of the Investigator's Global Assessment as the primary outcome for clinical trials in atopic dermatitis? by Bruin‐Weller, M.

“…Linked Article: Silverberg et al. Br J Dermatol 2019; 181:80–87…”
Get full text

Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials by Bieber, T., Thyssen, J.P., Reich, K., Simpson, E.L., Katoh, N., Torrelo, A., De Bruin‐Weller, M., Thaci, D., Bissonnette, R., Gooderham, M., Weisman, J., Nunes, F., Brinker, D., Issa, M., Holzwarth, K., Gamalo, M., Riedl, E., Janes, J.

“…Background Janus kinase (JAK) inhibition is a new mode of action in atopic dermatitis (AD); clarity about drug class safety considerations in the context of AD…”
Get full text

Anti‐IL‐5 recombinant humanized monoclonal antibody (Mepolizumab) for the treatment of atopic dermatitis by Oldhoff, J. M., Darsow, U., Werfel, T., Katzer, K., Wulf, A., Laifaoui, J., Hijnen, D. J., Plötz, S., Knol, E. F., Kapp, A., Bruijnzeel‐Koomen, C. A. F. M., Ring, J., Bruin‐Weller, M. S.

“…Background:  Eosinophils may play an important role in the pathogenesis of atopic dermatitis (AD). Interleukin‐5 is essential for eosinophil growth,…”
Get full text

Could conjunctivitis in patients with atopic dermatitis treated with dupilumab be caused by colonization with Demodex and increased interleukin‐17 levels?: reply from the authors by Bruin‐Weller, M., Graham, N.M.H., Pirozzi, G., Shumel, B.

“…Linked Article: de Bruin‐Weller et al. Br J Dermatol 2018; 178:1083–1101…”
Get full text

Higher levels of response on clinical atopic dermatitis severity measures are associated with meaningful improvements in patient‐reported symptom and quality of life measures: Integrated analysis of three Upadacitinib phase 3 trials by Reich, K., Bruin‐Weller, M. S., Deleuran, M., Calimlim, B. M., Chen, N., Hu, X., Tenorio, A. R., Silverberg, J. I.

“…Background It is not fully understood how different degrees of improvements in atopic dermatitis (AD) clinical outcome measures translate to improvements in…”
Get full text

A panel of biomarkers for disease severity in atopic dermatitis by Thijs, J. L., Nierkens, S., Herath, A., Bruijnzeel-Koomen, C. A. F., Knol, E. F., Giovannone, B., de Bruin-Weller, M. S., Hijnen, D.

Get full text

The patient‐reported disease burden in adults with atopic dermatitis: a cross‐sectional study in Europe and Canada by de Bruin‐Weller, M., Gadkari, A., Auziere, S., Simpson, E.L., Puig, L., Barbarot, S., Girolomoni, G., Papp, K., Pink, A.E., Saba, G., Werfel, T., Eckert, L.

“…Background Cross‐sectional data on patient burden in adults with atopic dermatitis (AD) from real‐world clinical practice are limited. Objective This study…”
Get full text

Upadacitinib for moderate‐to‐severe atopic dermatitis: Stratified analysis from three randomized phase 3 trials by key baseline characteristics by Thyssen, J. P., Thaçi, D., Bieber, T., Gooderham, M., Bruin‐Weller, M., Soong, W., Kabashima, K., Barbarot, S., Luna, P. C., Xu, J., Hu, X., Liu, Y., Raymundo, E. M., Calimlim, B. M., Nduaka, C., Gamelli, A., Simpson, E. L.

“…Background Atopic dermatitis (AD) is a heterogeneous inflammatory skin disease with different clinical phenotypes based on factors such as age, race,…”
Get full text

Systemic anti‐inflammatory treatment of atopic dermatitis during conception, pregnancy and breastfeeding: Interdisciplinary expert consensus in Northern Europe by Deleuran, M., Dézfoulian, B., Elberling, J., Knutar, I., Lapeere, H., Lossius, A. H., Schuttelaar, M. L. A., Stockman, A., Wikström, E., Bradley, M., Bruin‐Weller, M., Gutermuth, J., Mandelin, J. M., Schmidt, M. C., Thyssen, J. P., Vestergaard, C.

“…Treating atopic dermatitis (AD) in pregnant or breastfeeding women, and in women and men with AD aspiring to be parents is difficult and characterized by…”
Get full text

European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period by Vestergaard, C., Wollenberg, A., Barbarot, S., Christen‐Zaech, S., Deleuran, M., Spuls, P., Flohr, C., Trzeciak, M., von Kobyletzki, L., Seneschal, J., Paul, C., Bieber, T., Werfel, T., Fölster‐Holst, R., Darsow, U., Gieler, U., Svensson, Å., Cork, M., Stalder, J.‐F., De Raeve, L., Kunz, B., Simon, D., Chernyshov, P., Hijnen, D., Gelmetti, C., Ring, J., Taieb, A., de Bruin‐Weller, M., Thyssen, J.P.

“…Atopic dermatitis (AD) is a common inflammatory skin disease that affects both children and adults, including a large number of adults of reproductive age…”
Get full text

Abrocitinib effect on patient‐reported outcomes in patients with moderate‐to‐severe atopic dermatitis: Results from phase 3 studies, including the long‐term extension JADE EXTEND study by Reich, K., Silverberg, J. I., Papp, K. A., Deleuran, M., Katoh, N., Strober, B., Beck, L. A., Bruin‐Weller, M., Werfel, T., Zhang, F., Biswas, P., DiBonaventura, M. D., Chan, G., Farooqui, S. A., Kerkmann, U., Clibborn, C.

“…Background Abrocitinib improved signs and symptoms of moderate‐to‐severe atopic dermatitis (AD) at Weeks 12 and 16 in phase 3 studies, with a manageable safety…”
Get full text

Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement by Drucker, A.M., Eyerich, K., de Bruin‐Weller, M.S., Thyssen, J.P., Spuls, P.I., Irvine, A.D., Girolomoni, G., Dhar, S., Flohr, C., Murrell, D.F., Paller, A.S., Guttman‐Yassky, E.

“…Summary Background Guidelines discourage the use of systemic corticosteroids for atopic dermatitis (AD), but their use remains widespread. Objectives To reach…”
Get full text

Evaluation of the adult patient with atopic dermatitis by de Bruin Weller, M. S., Rockmann, H., Knulst, A. C., Bruijnzeel-Koomen, C. A. F. M.

“…Summary Atopic dermatitis (AD) is a chronic inflammatory skin disease with a large impact on quality of life of the patients and their families. In most cases,…”
Get full text